TGFB1 and cardiac hypertrophy: TGF-β has been demonstrated to be upregulated post-chemotherapeutic exposure in patients, which is, in turn, associated with increased fibrosis, cardiac hypertrophy and inflammation, impacting both short- and long-term patient prognosis [71,114,115,116,210].